Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma

Launched by HENAN CANCER HOSPITAL · Aug 21, 2019

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment for patients with advanced classical Hodgkin's lymphoma, a type of cancer that affects the lymphatic system. The researchers want to see how well a combination of a drug called Camrelizumab and a standard treatment called AVD works when given to patients who have not received any treatment before. The trial is currently looking for participants aged 18 to 75 who have been diagnosed with this advanced form of lymphoma, and who meet certain health criteria.

If you're eligible and decide to join the study, you'll receive the combination treatment and will be monitored closely by the medical team for any side effects and how well the treatment is working. This trial is important because it aims to find a safer and more effective first-line treatment option for Hodgkin's lymphoma, which could improve outcomes for patients. Participants will need to sign consent forms and may need to take precautions if they are able to become pregnant during the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age between 18 to 75 years old (including 18 and 75)
• • 2. Diagnosed as advanced classical hodgkin's lymphoma based on histopathology
• • 3. Subjects must be untreated (Ann Arbor Stage III/IV or Ann Arbor II with B symptoms along with mediastinal big tumor or extranodal changes)
• • 4. No receiving chemotherapy before enrollment
• • 5. Having at least one measurable lesions
• • 6. World health organization-Eastern Cooperative Oncology Group Performance Status (ECOG) 0-2
• • 7. Life expectancy no less than 3 months
• • 8. enough main organ function
• • 9. Pregnancy test within 7 days must be negative for women of childbearing period, and appropriate measures should be taken for contraception for women in childbearing period during the study and six months after this study
• • 10. Agreeing to sign the written informed consents
• Exclusion Criteria:
• • 1. Diagnosed as nodular lymphocyte predominant lymphoma or grey-zone lymphoma
• • 2. Diagnosed as central nervous system lymphoma
• • 3. usage of immunosuppressants before enrollment and the dose of immunosuppressant used \>10mg / day oral prednisone for more than 2 weeks
• • 4. Previously treated with anti-PD-1/PD-L1/PD-L2/CTLA-4
• • 5. Active autoimmune disease
• • 6. Vaccination with anti-tumor vaccine or other immune treatments less than 3 months
• • 7. Serious surgery and trauma less than two weeks
• • 8. Other malignant tumor history or active malignant tumor need be treated
• • 9. Systemic therapy for serious acute/chronic infection
• • 10. Congestive heart failure, uncontrolled coronary heart disease, arrhythmia and heart infarction less than 6 months
• • 11. Active tuberculosis
• • 12. Vaccination with live attenuated vaccine less than 4 weeks
• • 13. HIV-positive, AIDS patients and untreated active hepatitis
• • 14. Researchers determine unsuited to participate in this trial